Vision / Traction Organizer · Annual refresh

Eli Lilly and Company

LLY · Health Care · Generated Jul 21, 2026

Voice: Scientific, humane, disciplined · Lilly’s red, warm neutrals, clean sans type, and disciplined spacing mirror its patient-centered pharmaceutical brand.

Vision

Page 1

Core Values

Integrity
Do right
Excellence
Raise standards
Respect people
Dignity first
Patient focus
Patients first

Core Focus

Purpose / Cause / Passion

Make life better through medicines.

Our Niche

Innovative medicines for serious chronic disease.

10-Year Target

$150B revenue by 2036.

Marketing Strategy

Target Market

Patients with diabetes, obesity, cancer, immunology, and neuroscience needs.

Three Uniques

1.Incretin leadership
2.Biology-led R&D
3.Global manufacturing scale

Proven Process

1.Discover
2.Validate
3.Develop
4.Manufacture
5.Gain access
6.Launch
7.Monitor outcomes

Guarantee

Every approved medicine meets global quality specifications.

Traction

Page 2

3-Year Picture

Future date: Dec 31, 2029

Revenue

$105B revenue

Profit

$45B non-GAAP operating income

What it looks like

Obesity capacity meets demand.
Orforglipron launched globally.
Kisunla established in Alzheimer's care.
Cardiometabolic franchise diversified.
Oncology pipeline delivering approvals.
Access strengthened across major markets.

1-Year Plan

Future date: Dec 31, 2027

Revenue

$80B revenue

Profit

$31B non-GAAP operating income

Goals

1.Deliver $80B revenue.
2.Reach $31B operating income.
3.Add 25% incretin capacity.
4.Submit orforglipron in major markets.
5.Expand Zepbound access by 10M lives.

Rocks

This quarter

David A. Ricks
Obesity leadership plan
Deliver $80B revenue while protecting access and trust.
Edgardo Hernandez
Incretin capacity expansion
Increase sellable incretin capacity by 25% by year-end.
Daniel M. Skovronsky
Orforglipron regulatory package
Complete major-market submissions for oral GLP-1 by Q4.
Patrik Jonsson
Zepbound access expansion
Add 10M covered lives and improve fulfillment reliability.
Lucas Montarce
Margin discipline reset
Reach $31B non-GAAP operating income for 2027.

Issues List

1.GLP-1 supply behind demand.source
2.Counterfeit and compounded tirzepatide risk.source
3.US pricing pressure rising.source
4.Obesity competition intensifying.source
5.Alzheimer's uptake remains slow.source
6.Manufacturing capex execution risk.source

Sources

Illustrative V/TO in the EOS format for Eli Lilly and Company. Not affiliated with or endorsed by the company. Generated from public information; treat as a strategy exercise.